It was about our premium positioning, which drove further expansion in our gross profit margin to 61.5% and our adjusted EBITDA margin to 18.2%. For example, fans saw Iga Swiatec win an incredible ...
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today reported financial results for the ...
Global sustainable funds faced net outflows of approximately USD 55 billion in Q3 2025, a sharp reversal from the USD 5.8 billion inflows in the previous quarter. This shift was driven primarily by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback